United Therapeutics (NASDAQ:UTHR) Downgraded to Sell at ValuEngine

ValuEngine downgraded shares of United Therapeutics (NASDAQ:UTHR) from a hold rating to a sell rating in a report published on Tuesday morning, ValuEngine reports.

Other research analysts have also recently issued research reports about the stock. Wedbush lifted their price objective on shares of United Therapeutics from $269.00 to $273.00 and gave the company an outperform rating in a report on Thursday, May 2nd. Credit Suisse Group upgraded shares of United Therapeutics from an underperform rating to a neutral rating and set a $98.00 price objective for the company in a report on Thursday, May 9th. BidaskClub cut shares of United Therapeutics from a hold rating to a sell rating in a report on Friday, April 19th. Cowen restated a hold rating and issued a $103.00 price objective on shares of United Therapeutics in a report on Wednesday, May 1st. Finally, LADENBURG THALM/SH SH set a $124.00 price objective on shares of United Therapeutics and gave the company a hold rating in a report on Thursday, February 28th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. United Therapeutics currently has an average rating of Hold and a consensus price target of $129.00.

United Therapeutics stock opened at $80.76 on Tuesday. The company has a market capitalization of $3.59 billion, a PE ratio of 6.03 and a beta of 1.15. United Therapeutics has a 1 year low of $80.10 and a 1 year high of $130.00. The company has a current ratio of 7.19, a quick ratio of 6.84 and a debt-to-equity ratio of 0.45.



United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($13.96). The company had revenue of $362.70 million during the quarter, compared to analysts’ expectations of $335.72 million. United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. United Therapeutics’s revenue was down 6.8% on a year-over-year basis. During the same period last year, the firm posted $3.76 earnings per share. On average, research analysts forecast that United Therapeutics will post -5.03 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Fort L.P. acquired a new position in United Therapeutics during the 1st quarter worth approximately $25,000. Captrust Financial Advisors grew its holdings in United Therapeutics by 384.9% during the 4th quarter. Captrust Financial Advisors now owns 257 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 204 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new position in United Therapeutics during the 1st quarter worth approximately $29,000. Oregon Public Employees Retirement Fund grew its holdings in United Therapeutics by 10,537.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 3,551,229 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 3,517,845 shares in the last quarter. Finally, First Mercantile Trust Co. grew its holdings in United Therapeutics by 47.8% during the 4th quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 110 shares in the last quarter. Institutional investors own 96.47% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

See Also: Cost of Capital

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.